Creatd Files Q1 2026 Results and SEC Registration Statement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: Newsfilter
- Financial Overview: For Q1 2026, Creatd reported approximately $204,000 in revenue and $202,000 in gross profit, despite facing significant non-cash charges of about $11.3 million in stock-based compensation, which materially impacted net income but did not affect cash position or enterprise value.
- Balance Sheet Improvement: The company received approximately $5.6 million in preferred stock receivables and $4.8 million in promissory notes from the sale of Flyte to Catheter Precision, Inc., resulting in total assets of approximately $12.1 million, indicating positive progress in asset management.
- Capital Structure Simplification: Founder and CEO Jeremy Frommer has converted certain preferred stock and warrants into common stock, aimed at simplifying the capital structure and aligning management with shareholders to support the long-term goal of uplisting to a national securities exchange.
- Annual Meeting Update: Creatd has revised the record date for its 2026 Annual Meeting of Shareholders to June 26, 2026, with the meeting now scheduled for August 3, 2026, providing shareholders additional time to review recent filings and developments, thereby enhancing transparency and shareholder engagement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTAK
About VTAK
Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. Its two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is also a technology-enabled regional air mobility company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Creatd Files Q1 2026 Results and SEC Registration Statement
- Financial Overview: For Q1 2026, Creatd reported approximately $204,000 in revenue and $202,000 in gross profit, despite facing significant non-cash charges of about $11.3 million in stock-based compensation, which materially impacted net income but did not affect cash position or enterprise value.
- Balance Sheet Improvement: The company received approximately $5.6 million in preferred stock receivables and $4.8 million in promissory notes from the sale of Flyte to Catheter Precision, Inc., resulting in total assets of approximately $12.1 million, indicating positive progress in asset management.
- Capital Structure Simplification: Founder and CEO Jeremy Frommer has converted certain preferred stock and warrants into common stock, aimed at simplifying the capital structure and aligning management with shareholders to support the long-term goal of uplisting to a national securities exchange.
- Annual Meeting Update: Creatd has revised the record date for its 2026 Annual Meeting of Shareholders to June 26, 2026, with the meeting now scheduled for August 3, 2026, providing shareholders additional time to review recent filings and developments, thereby enhancing transparency and shareholder engagement.
See More
Small Caps Surge on Partnerships and Policy Initiatives
- Catheter Precision Partnership: Catheter Precision's Flyte unit partnered with GSE Worldwide to launch Cirrus Vision Jet services aimed at enhancing travel experiences for professional athletes, resulting in a nearly 61% surge in stock price during after-hours trading.
- Quantum Technology Policy: President Trump signed two executive orders to accelerate U.S. quantum technology development, leading to a more than 12% increase in Infleqtion's stock, which expressed support for these initiatives to bolster U.S. leadership in emerging tech.
- Oriental Rise Reverse Split: Oriental Rise Holdings executed a 1-for-4 reverse stock split, causing its stock price to rise 22% in after-hours trading as investors interpreted the reduced share count and increased price as a tightening of trading liquidity.
- Market Sentiment Shift: All three companies experienced strong investor interest in after-hours trading, with retail sentiment for Catheter Precision and Oriental Rise Holdings shifting from 'bullish' to 'extremely bullish', indicating positive market expectations for small-cap stocks.
See More
Flyte Partners with GSE Worldwide to Enhance Athlete Travel Solutions
- Partnership Launch: Flyte's collaboration with GSE Worldwide and PGA professional Emiliano Grillo commenced during the 2026 U.S. Open, marking a significant step in Flyte's expansion into professional sports to meet the travel needs of athletes.
- Athlete Performance: Emiliano Grillo showcased his skills at the 2026 U.S. Open, reaching as high as third place before finishing tied for 23rd, highlighting the potential of Flyte's partnership with elite athletes.
- Market Demand: With the growing need for efficient regional travel solutions among professional athletes, Flyte's Cirrus Vision Jets offer a faster and more flexible alternative to traditional travel methods, aimed at optimizing athletes' time management.
- Strategic Vision: Flyte's CEO Marc Sellouk emphasized that this partnership supports Flyte's growth strategy and aims to build meaningful relationships within the GSE network, further enhancing Flyte's presence in the professional sports arena.
See More
Flyte Makes Strategic Investment in Volato Group
- Investment Overview: Flyte, the regional air mobility subsidiary of Catheter Precision, Inc., announced the acquisition of approximately 2.9 million shares of Volato Group, Inc., resulting in a 7.5% ownership stake aimed at enhancing accessibility and flexibility in private aviation.
- Collaboration Potential: This investment lays the groundwork for future collaboration, as the strategic relationship between Flyte and Volato is expected to improve service efficiency and innovation, thereby creating long-term shareholder value for both companies.
- Market Expansion Strategy: Flyte's investment supports its strategy to expand its aviation ecosystem, aiming to drive business growth and enhance its AI platform capabilities through partnerships within the industry.
- Shareholder Value Enhancement: Volato's CEO noted that this investment not only provides growth capital but also introduces a highly aligned strategic shareholder, which is anticipated to unlock more collaborative opportunities for shareholders.
See More
Volato Group Secures $2.2M Strategic Investment
- Strategic Investment Agreement: Volato Group has signed a definitive agreement for a $2.2 million strategic equity investment led by Catheter Precision, significantly strengthening its balance sheet following the termination of its deal with M2i Global.
- Core Strategic Shift: The capital injection will support Volato's strategic pivot towards the artificial intelligence ecosystem, specifically targeting potential mergers and acquisitions in AI software, data infrastructure, compute, and power generation sectors, indicating a proactive approach to future growth.
- Acquisition Letters of Intent: Volato has received two unsolicited, non-binding letters of intent regarding potential transactions involving AI data center infrastructure and dedicated power generation assets, reflecting market recognition of its strategic direction and potentially accelerating its expansion in the AI sector.
- Shareholder Structure Change: Following this investment, Catheter Precision becomes Volato's largest shareholder, further solidifying its critical role in the company's strategic development, while the investment remains subject to customary closing conditions from NYSE American.
See More
Volato Secures $2.2 Million Strategic Investment to Shift Focus to AI
- Strategic Investment Background: Volato announced a $2.2 million strategic investment aimed at strengthening its balance sheet and refocusing on artificial intelligence, led by Catheter Precision, marking a pivot from an unsuccessful critical minerals merger to pursuing AI infrastructure opportunities.
- Impact of Deal Termination: This investment follows the termination of Volato's transaction with M2i Global, which would have transformed the company into a critical and strategic mineral reserve play, with management believing this shift aligns better with the company's technology assets and long-term shareholder value.
- Market Opportunity Validation: Volato received two unsolicited, non-binding letters of intent related to potential deals within the AI ecosystem, including AI data center infrastructure and power generation assets supporting AI workloads; although no agreements have been reached, management views this as validation of its AI pivot.
- Market Reaction: Despite Volato's stock dropping 23% in premarket trading on Monday, retail sentiment on Stocktwits remains 'extremely bullish', indicating strong market interest in the company's future AI strategy, even as its stock has declined over 45% this year.
See More
Creatd Files Q1 2026 Results and SEC Registration Statement
- Financial Overview: For Q1 2026, Creatd reported approximately $204,000 in revenue and $202,000 in gross profit, despite facing significant non-cash charges of about $11.3 million in stock-based compensation, which materially impacted net income but did not affect cash position or enterprise value.
- Balance Sheet Improvement: The company received approximately $5.6 million in preferred stock receivables and $4.8 million in promissory notes from the sale of Flyte to Catheter Precision, Inc., resulting in total assets of approximately $12.1 million, indicating positive progress in asset management.
- Capital Structure Simplification: Founder and CEO Jeremy Frommer has converted certain preferred stock and warrants into common stock, aimed at simplifying the capital structure and aligning management with shareholders to support the long-term goal of uplisting to a national securities exchange.
- Annual Meeting Update: Creatd has revised the record date for its 2026 Annual Meeting of Shareholders to June 26, 2026, with the meeting now scheduled for August 3, 2026, providing shareholders additional time to review recent filings and developments, thereby enhancing transparency and shareholder engagement.
See More
Small Caps Surge on Partnerships and Policy Initiatives
- Catheter Precision Partnership: Catheter Precision's Flyte unit partnered with GSE Worldwide to launch Cirrus Vision Jet services aimed at enhancing travel experiences for professional athletes, resulting in a nearly 61% surge in stock price during after-hours trading.
- Quantum Technology Policy: President Trump signed two executive orders to accelerate U.S. quantum technology development, leading to a more than 12% increase in Infleqtion's stock, which expressed support for these initiatives to bolster U.S. leadership in emerging tech.
- Oriental Rise Reverse Split: Oriental Rise Holdings executed a 1-for-4 reverse stock split, causing its stock price to rise 22% in after-hours trading as investors interpreted the reduced share count and increased price as a tightening of trading liquidity.
- Market Sentiment Shift: All three companies experienced strong investor interest in after-hours trading, with retail sentiment for Catheter Precision and Oriental Rise Holdings shifting from 'bullish' to 'extremely bullish', indicating positive market expectations for small-cap stocks.
See More
Flyte Partners with GSE Worldwide to Enhance Athlete Travel Solutions
- Partnership Launch: Flyte's collaboration with GSE Worldwide and PGA professional Emiliano Grillo commenced during the 2026 U.S. Open, marking a significant step in Flyte's expansion into professional sports to meet the travel needs of athletes.
- Athlete Performance: Emiliano Grillo showcased his skills at the 2026 U.S. Open, reaching as high as third place before finishing tied for 23rd, highlighting the potential of Flyte's partnership with elite athletes.
- Market Demand: With the growing need for efficient regional travel solutions among professional athletes, Flyte's Cirrus Vision Jets offer a faster and more flexible alternative to traditional travel methods, aimed at optimizing athletes' time management.
- Strategic Vision: Flyte's CEO Marc Sellouk emphasized that this partnership supports Flyte's growth strategy and aims to build meaningful relationships within the GSE network, further enhancing Flyte's presence in the professional sports arena.
See More
Flyte Makes Strategic Investment in Volato Group
- Investment Overview: Flyte, the regional air mobility subsidiary of Catheter Precision, Inc., announced the acquisition of approximately 2.9 million shares of Volato Group, Inc., resulting in a 7.5% ownership stake aimed at enhancing accessibility and flexibility in private aviation.
- Collaboration Potential: This investment lays the groundwork for future collaboration, as the strategic relationship between Flyte and Volato is expected to improve service efficiency and innovation, thereby creating long-term shareholder value for both companies.
- Market Expansion Strategy: Flyte's investment supports its strategy to expand its aviation ecosystem, aiming to drive business growth and enhance its AI platform capabilities through partnerships within the industry.
- Shareholder Value Enhancement: Volato's CEO noted that this investment not only provides growth capital but also introduces a highly aligned strategic shareholder, which is anticipated to unlock more collaborative opportunities for shareholders.
See More
Volato Group Secures $2.2M Strategic Investment
- Strategic Investment Agreement: Volato Group has signed a definitive agreement for a $2.2 million strategic equity investment led by Catheter Precision, significantly strengthening its balance sheet following the termination of its deal with M2i Global.
- Core Strategic Shift: The capital injection will support Volato's strategic pivot towards the artificial intelligence ecosystem, specifically targeting potential mergers and acquisitions in AI software, data infrastructure, compute, and power generation sectors, indicating a proactive approach to future growth.
- Acquisition Letters of Intent: Volato has received two unsolicited, non-binding letters of intent regarding potential transactions involving AI data center infrastructure and dedicated power generation assets, reflecting market recognition of its strategic direction and potentially accelerating its expansion in the AI sector.
- Shareholder Structure Change: Following this investment, Catheter Precision becomes Volato's largest shareholder, further solidifying its critical role in the company's strategic development, while the investment remains subject to customary closing conditions from NYSE American.
See More
Volato Secures $2.2 Million Strategic Investment to Shift Focus to AI
- Strategic Investment Background: Volato announced a $2.2 million strategic investment aimed at strengthening its balance sheet and refocusing on artificial intelligence, led by Catheter Precision, marking a pivot from an unsuccessful critical minerals merger to pursuing AI infrastructure opportunities.
- Impact of Deal Termination: This investment follows the termination of Volato's transaction with M2i Global, which would have transformed the company into a critical and strategic mineral reserve play, with management believing this shift aligns better with the company's technology assets and long-term shareholder value.
- Market Opportunity Validation: Volato received two unsolicited, non-binding letters of intent related to potential deals within the AI ecosystem, including AI data center infrastructure and power generation assets supporting AI workloads; although no agreements have been reached, management views this as validation of its AI pivot.
- Market Reaction: Despite Volato's stock dropping 23% in premarket trading on Monday, retail sentiment on Stocktwits remains 'extremely bullish', indicating strong market interest in the company's future AI strategy, even as its stock has declined over 45% this year.
See More
